Track and Submission Category Details
Abstract Submission
Deadline: May 29, 2024 at 11:59 PM ET
SNO’s Special Interest Tracks serve to support the Society’s educational and scientific efforts by providing an additional layer of subject matter expertise in the planning of our conferences and events. Please use the following guidelines when selecting a Special Interest Track and Abstract Category.
NOTE: Upon review, the SNO Annual Meeting Planning Committee reserves the right to change the special interest track and category originally selected by the abstract submitter.
SPECIAL INTEREST TRACKS:
- Basic Science – Investigations focused on determining the causal mechanisms of tumors affecting the brain, spinal cord, and peripheral nerves.
- Cancer Neuroscience – Investigations focused on nervous system activity regulation of cancer initiation and growth in addition to mechanisms by which cancer and cancer therapies affect nervous system activity.
- Clinical Trials – Research studies that test medical, surgical, or behavioral interventions in patients.
- CNS Metastases –Research studies focused on cancer that has spread from a primary solid organ to the central nervous system.
- CNS Rare Tumors – Investigations focused on central nervous system tumors with an incidence rate below the threshold defining rare disease.
- Heath Disparities-Social Determinants of Health – Research studies focused on differences in overall health, burden of disease, or health outcomes between populations that are attributable to social, economic, gender, racial, and or environmental factors.
- Molecular Pathology – Research studies involving the use of genomic material to diagnose, classify, and measure the course of disease or response to tumor therapies.
- Neurogenetic Tumor Syndromes – Research studies focused on outcomes and/or causal mechanisms of genetic tumor syndromes with associated intracranial neoplasms.
- Neurohematology – Investigations focused on hematolymphoid malignancies of the central nervous system.
- Neuroimaging– Research studies focused on structural, metabolic, or functional imaging to assess neoplasms of the central nervous system.
- Neurology of Cancer – Investigations focused on neurocognitive effects or neurological complications of cancer care.
- Neurosurgery – Research studies focused on surgical therapies and drug delivery for brain malignancies.
- Pediatrics – Research studies focused on basic, clinical, and translational sciences for children, adolescence, and young adults with central nervous system malignancies.
- Quality Improvement- Investigations focused on systemic actions that lead to measurable improvements in health care services and health status of targeted patient groups.
- Radiation Sciences – Investigations focused on clinical radiotherapy and radiobiology for the treatment of central nervous system malignancies.
- Survivorship – Research studies focused on innovations in patient care, quality of life, palliative care, and end of life for patients with central nervous system malignancies.
- Late Breaking Abstracts - Late phase clinical trial abstract submissions submitted following interim or final analysis.
2024 SNO ANNUAL MEETING SUBMISSION CATEGORIES:
- Angiogenesis and Invasion
- Biomarkers
- Biostatistics
- Cancer Neuroscience
- Cancer Stem Cell
- Cell Cycle Regulation
- Cell Signaling and Signaling Pathways
- Clinical Radiotherapy
- Clinical Trials: Immunologic
- Clinical Trials: Non-immunologic
- DNA Repair/Modulation
- Drug Delivery
- Drug Discovery, Drug Resistance
- (Epi)Genetics and Computational Omics
- End of Life and Palliative Care
- Epidemiology
- Health Disparities and Equity
- Immunobiology
- Innovations in Patient Care
- Molecular Pathology & Classification
- Neuro-imaging
- Neurological Complications of Cancer
- Outcome Measures and Neuro-Cognitive Outcomes
- Preclinical Experimental Therapeutics
- Quality Improvement
- Quality of Life
- Radiobiology
- Randomized Trials in Development
- Surgical Therapies
- Tumor Metabolism
- Tumor Microenvironment
- Tumor Models
- Late Breaking - Clinical Trials: Immunologic
- Late Breaking - Clinical Trials: Non-Immunologic